Incyte announces first patient treated in phase 3 clinical trial of itacitinib for GVHD
Incyte announced the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease. The trial will evaluate efficacy and safety of itacitinib, Incyte’s novel and selective JAK1 inhibitor. January 22, 2019